print-logo
Logo
  • Healthcare Consultants
  • Healthcare Managers
  • Who we are Arrow Down
    • About us
    • Our purpose & values
    • Our team
    • News & events
  • What we do Arrow Down
    • Overview
    • Market Access
    • Medical Affairs
    • Government Affairs
    • Commercial
    • Patient Advocacy
    • Lifecycle Management
  • Insights Arrow Down
    • Publications
    • Project cases
    • Early Asset Strategy
    • Value Pull-Through
    • Environment Transformation
  • Careers Arrow Down
    • Why join us
    • Open positions
    • Career paths
    • FAQ
  • Contact
  • Search Icon
  • Healthcare Consultants
  • Healthcare Managers
  • Search Icon
  • Search
Back to Publications
  • linkedin_icon
  • twitter_icon
  • mail_icon
  • print_icon
  • download

Patient centricity standards, criteria and KPIs across the biopharma industry (Part 1)

Looking for optimal standards, criteria and KPIs of patient centricity across the biopharma industry: an overview of existing frameworks and conceptual models

Patient centricity standards, criteria and KPIs across the biopharma industry (Part 1)

Download Part I:

https://www.executiveinsight.ch/application/files/2415/9342/0525/Patient_centricity_KPIs_and_standards_review-part_1-Merlin_Williams.pdf

Download Part II:

https://www.executiveinsight.ch/application/files/2016/0983/1612/Patient_engagement_article_part_2_Merlin_Williams.pdf


The biopharmaceutical industry is still on the path to patient centricity, in which a key challenge is to establish new ways of working, key performance indicators and operational models. There is currently no unified approach to measuring the success of patient engagement and patient centricity across the industry.

Methods

A literature search and broader resource analysis was conducted to identify and select frameworks, conceptual models and other relevant initiatives across the biopharmaceutical industry and healthcare systems focused on performance management and success evaluation within patient centeredness, over the period of 2010-2019. The selected resources were initially assessed against their key characteristics, targeted stakeholders, medicine lifecycle stage and proposed key elements (standards, attributes, criteria, KPIs and other indicators). Following, a deep content-analysis of the key elements was conducted, in which the key elements were categorised based on being attributable or infrastructural/procedural.

Results

192 results were found through the literature search and 13 from the broader resource analysis. 12 frameworks and conceptual models were identified and selected as relevant; 4 targeted to the industry and 8 targeted to several stakeholders, including industry. Analysis of the selected frameworks/conceptual models demonstrated their significant diversity, heterogeneity and inconsistency in terms of their presented format, purpose, key objectives, targeted medicine lifecycle stage or industry/healthcare operations and proposed key elements. Categorisation of the 30 key elements led to 11 as attributable elements and 19 as infrastructural/procedural elements. Certain key elements featured higher cross-referencing within the analysed frameworks/conceptual models: diversity and representativeness, reciprocity, transparency, capacity and capabilities for engagement, meaningfulness, roles and responsibilities (attributable elements), valued products and quality product information (infrastructural/procedural element).

Conclusions

There is a first attempt to categorise and analyse the frameworks and conceptual models of patient centricity developed over the last decade. These findings should be the subject for further research and publications, in particular with the focus on piloting, validation and broader adoption of certain patient-centric standards, impact indicators and/or KPIs across the several organisations of biopharmaceutical industry.

Authors

Williams Merlin – MSc, Senior Consultant, Executive Insight Healthcare Consultants AG, Baar, Switzerland.
m.williams@executiveinsight.ch

Gorbenko Oleksandr – MD, PhD, Global Director, Patient Affairs, ViiV Healthcare, TW8 9GS, 980 Great West Road, Brentford, Middlesex, United Kingdom.
algostand@gmail.com
 

This study has been published in the Ukrainian Journal of Public Health, which adheres to the International Committee on Publication Ethics.

Download PDF 351.9 KB

Contact our experts

Merlin Williams

Merlin Williams

Manager

mail_icon linkedin_icon

Related Publications

Publication Preview Image

September 09 2020

Patient centricity standards, criteria and KPIs across the biopharma industry (Part 2)

Publication Preview Image

October 10 2016

Orphan drugs – leading the way in patient centricity

Publication Preview Image

May 29 2017

Nothing about us without us!

Publication Preview Image

May 29 2017

Power to the people

Publication Preview Image

March 21 2017

Engaging patients right from the start

Publication Preview Image

October 11 2016

Achieving patient centricity: 4 key lessons from orphan disease companies

Share this page
  • linkedin_icon
  • twitter_icon
  • mail_icon
  • print_icon

We use cookies to ensure we give you the best experience on our website. Detailed information on the use of cookies, and how you can disable them, is provided in our Privacy Policy. By using this site or clicking on "OK", you consent to the use of cookies.

OK
arrow_up

How can we help?

Contact us

Our offices

Careers

Footer Logo
  • Who we are
  • What we do
  • Insights
  • Careers
  • Contact
  • Terms of use
  • Privacy policy
  • Imprint

2023 Executive Insight. All rights reserved.